These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Correlates of cannabis use in a sample of mental health treatment-seeking Canadian armed forces members and veterans. St Cyr K; Nazarov A; Le T; Nouri M; Saha P; Forchuk CA; Soares V; Wanklyn SG; Bird BM; Davis BD; King L; Ketcheson F; Richardson JD BMC Psychiatry; 2023 Nov; 23(1):836. PubMed ID: 37964206 [TBL] [Abstract][Full Text] [Related]
27. Challenges for Clinical Cannabis and Cannabinoid Research in the United States. Cooper ZD; Abrams DI; Gust S; Salicrup A; Throckmorton DC J Natl Cancer Inst Monogr; 2021 Nov; 2021(58):114-122. PubMed ID: 34850896 [TBL] [Abstract][Full Text] [Related]
28. A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids. Brewer TL; Collins M J Spec Pediatr Nurs; 2014 Apr; 19(2):119-26. PubMed ID: 24320158 [TBL] [Abstract][Full Text] [Related]
29. Comparison of hospital claims and poison center data to evaluate health impact of opioids, cannabis and synthetic cannabinoids. Wang GS; Buttorff C; Wilks A; Schwam D; Tung GJ; Banerji S; Dart RC; Pacula RL Am J Emerg Med; 2022 Mar; 53():150-153. PubMed ID: 35051702 [TBL] [Abstract][Full Text] [Related]
30. Do police arrestees substitute legal highs for other drugs? Wilkins C; Parker K; Prasad J; Jawalkar S Int J Drug Policy; 2016 May; 31():74-9. PubMed ID: 26948501 [TBL] [Abstract][Full Text] [Related]
31. International trends in spice use: Prevalence, motivation for use, relationship to other substances, and perception of use and safety for synthetic cannabinoids. Loeffler G; Delaney E; Hann M Brain Res Bull; 2016 Sep; 126(Pt 1):8-28. PubMed ID: 27108542 [TBL] [Abstract][Full Text] [Related]
32. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Tait RJ; Caldicott D; Mountain D; Hill SL; Lenton S Clin Toxicol (Phila); 2016; 54(1):1-13. PubMed ID: 26567470 [TBL] [Abstract][Full Text] [Related]
33. A naturalistic study of orally administered vs. inhaled legal market cannabis: cannabinoids exposure, intoxication, and impairment. Bidwell LC; Karoly HC; Torres MO; Master A; Bryan AD; Hutchison KE Psychopharmacology (Berl); 2022 Feb; 239(2):385-397. PubMed ID: 34708254 [TBL] [Abstract][Full Text] [Related]
34. Cannabinoids for Treatment of MS Symptoms: State of the Evidence. Rice J; Cameron M Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025 [TBL] [Abstract][Full Text] [Related]
35. Spicing up the military: Use and effects of synthetic cannabis in substance abusing army personnel. Walker D; Neighbors C; Walton T; Pierce A; Mbilinyi L; Kaysen D; Roffman R Addict Behav; 2014 Jul; 39(7):1139-44. PubMed ID: 24727109 [TBL] [Abstract][Full Text] [Related]
37. 'Synthetic cannabis': A dangerous misnomer. Darke S; Banister S; Farrell M; Duflou J; Lappin J Int J Drug Policy; 2021 Dec; 98():103396. PubMed ID: 34343944 [TBL] [Abstract][Full Text] [Related]
38. Use and effects of cannabinoids in military veterans with posttraumatic stress disorder. Betthauser K; Pilz J; Vollmer LE Am J Health Syst Pharm; 2015 Aug; 72(15):1279-84. PubMed ID: 26195653 [TBL] [Abstract][Full Text] [Related]
39. Synthetic cannabinoid use in psychiatric patients and relationship to hospitalisation: A retrospective electronic case register study. Hobbs M; Patel R; Morrison PD; Kalk N; Stone JM J Psychopharmacol; 2020 Jun; 34(6):648-653. PubMed ID: 32108548 [TBL] [Abstract][Full Text] [Related]